Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers

Clinica Chimica Acta

Volumn 386, Issue 1-2, 2007, Pages 25-30

  Lv, Hua ^a   Sun, Jian Guo ^a   Wang, Guang Ji ^a   Zhu, Xiao Yan ^a   Zhang, Ying ^a   Gu, Sheng Hua ^a   Liang, Yan ^a   Sun, Jie ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Liquid chromatography electrospray tandem mass spectrometry; Pharmacokinetics; Pitavastatin

Indexed keywords

ETHER; MEVINOLIN; PITAVASTATIN;

ACCURACY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL PROTOCOLS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; PILOT PROJECTS; QUINOLINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VOLUNTARY WORKERS;

EID: 34548861762     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.07.022     Document Type: Article

References (9)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 344 (1994) 1383-1389
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
4. Bertolini S., Bon G.B., Campbell L.M., Farnier M., Langan J., Mahla G., et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 130 (1997) 191-197
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
6. Aoki T., Nishimura H., Nakagawa S., Kojima J., Suzuki H., Tamaki T., et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47 (1997) 904-909
7. Saito Y., Yamada N., Teramoto T., Itakura H., Hata Y., Nakaya N., et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolaemia. Atherosclerosis 162 (2002) 373-379
8. Kojima J., Fujino H., Yosimura M., Morikawa H., and Kimata H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 724 (1999) 173-180
9. Hui C.K., Cheunq B.M., and Lau G.K. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 59 3 (2005) 291-297